Previous Article | Next Article 
Journal of Virology, June 1999, p. 4622-4630, Vol. 73, No. 6
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Mutational Analysis, Using a Full-Length Rubella Virus cDNA
Clone, of Rubella Virus E1 Transmembrane and Cytoplasmic
Domains Required for Virus Release
Jiansheng
Yao and
Shirley
Gillam*
Department of Pathology and Laboratory
Medicine, Research Institute, University of British Columbia,
Vancouver, British Columbia V5Z 4H4, Canada
Received 10 July 1998/Accepted 23 February 1999
 |
ABSTRACT |
We report on the construction of a full-length cDNA clone, pBRM33,
derived from wild-type rubella virus M33 strain. The RNA transcripts
synthesized in vitro from pBRM33 are highly infectious, and the viruses
produced retain the phenotypic characteristics of the parental M33
virus in growth rate and plaque size. This cDNA clone was used to study
the role of E1 transmembrane and cytoplasmic domains in virus assembly
by site-directed mutagenesis. Three different alanine substitutions
were introduced in the transmembrane domain of E1. These included
substitution of leucine 464, cysteine 466, cysteine 467, and both
cysteines 466 and 467 to alanine. In the E1 cytoplasmic domain,
cysteine 470 and leucine 471 were altered to alanine. We found that
these mutations did not significantly affect viral RNA replication,
viral structural protein synthesis and transport, or E2/E1 heterodimer
formation. Except for the substitution of cysteine 470, these mutations
did, however, lead to a reduction in virus release. Substitution of
cysteine 467 in the transmembrane region and of leucine 471 in the
cytoplasmic domain dramatically reduced virus yield, resulting in the
production of only 1 and 10% of the parental virus yield,
respectively, in a parallel infection. These data show that E1
transmembrane and cytoplasmic domains play an important role in late
stages of virus assembly, possibly during virus budding, consistent
with earlier studies indicating that the E1 cytoplasmic domain may
interact with nucleocapsids and that this interaction drives virus budding.
 |
INTRODUCTION |
Rubella virus (RV), the etiological
agent of German measles, is the only member of the Rubivirus
genus in the Togaviridae family (15). This family
also includes the Alphavirus genus, containing the Sindbis
and Semiliki Forest viruses. RV uses a strategy similar to that of
alphaviruses in gene replication and expression (7). The RNA
genome of RV is 9,758 nucleotides (nt) in length, exclusive of a cap
structure and a poly(A) tract (6, 22). The 5' two-thirds of
the genome encodes nonstructural proteins, and the 3' one-third encodes
structural proteins. The nonstructural proteins are translated from the
genomic RNA as a polyprotein precursor, which is cleaved by a
virus-encoded protease into two nonstructural proteins, p150 and p90
(3, 29). These two proteins are thought to form a
replication complex with host factors and to be involved in RNA
replication. The subgenomic RNA corresponding to the 3' one-third of
the genome is synthesized from the genomic RNA and used as a template
for translation of structural proteins (4, 5, 18).
RV virions contain an icosahedral nucleocapsid surrounded by a lipid
envelope in which two virus-encoded glycoproteins, E1 and E2, are
embedded (7, 26). The structural proteins are synthesized as
a polyprotein precursor in the order capsid-E2-E1 (17). This
is translocated into the endoplasmic reticulum (ER) by two
independently functioning signal peptides within the carboxy terminus
of capsid and E2 (9, 12). In the ER, the polyprotein precursor is cleaved by a signal peptidase into the three structural proteins, capsid, E2, and E1 (10, 16). Multiple copies of capsid bind to the genomic RNA to form nucleocapsids in the cytoplasm, and the glycoproteins E2 and E1 form a specific heterodimer in the ER
shortly after synthesis (1, 7). The E2/E1 heterodimers are
transported out of the ER to the Golgi and plasma membranes, where the
virus matures by the budding of nucleocapsids through cellular
membranes to acquire the viral envelope. In BHK cells, the primary
budding site for RV is at the Golgi membrane, although budding at the
plasma membrane occurs in Vero cells (7, 11). In this
regard, RV is different from alphaviruses, which bud exclusively at the
plasma membrane (25). However, like alphaviruses, this budding process appears to be capsid dependent, since formation of
virus-like particles by transfection of subgenomic cDNA into BHK cells
is strictly dependent on the expression of glycoproteins E2 and E1 and
capsid (11, 24). In alphaviruses, genetic studies by
construction of chimeric viruses demonstrated that the cytoplasmic domain of glycoprotein E2 interacts with the nucleocapsid in a sequence-specific fashion during virus budding (14).
Site-directed mutations with infectious cDNA clones revealed that two
amino acids, tyrosine and leucine, at the amino terminus of the E2
cytoplasmic domain play a critical role in the interaction (19,
30). The role of glycoproteins E1 and E2 in RV assembly is not
well defined. RV E2 and E1 are anchored in the membrane as a type 1 membrane protein. The putative E2 transmembrane sequence is 39 residues in length, followed by a positively charged sequence, RRACRRR, and a stretch of 20 hydrophobic residues that is reinserted into the ER membrane and serves as the signal sequence for E1. The putative
E1 transmembrane domain is 22 residues in length and is followed by a
stretch of 13 amino acids that forms the cytoplasmic domain of E1. It
is suggested that this 13-amino-acid stretch of E1 may play a role in
mediating the interaction of glycoproteins with nucleocapsids in RV
assembly (11).
In this study, we describe the construction of a full-length infectious
cDNA clone of the M33 strain. RNA transcribed from the cDNA clone
produced infectious virus that showed the same characteristics as the
parental virus M33 strain in growth and plaque size. We have used this
infectious cDNA clone to investigate the role of E1 cytoplasmic and
transmembrane domains in viral assembly by introduction of mutations in
these regions. Our data showed that mutation of cysteine 467 at the C
terminus of the E1 transmembrane domain and leucine 471 at the N
terminus of the E1 cytoplasmic domain dramatically reduced virus release.
 |
MATERIALS AND METHODS |
Virus and cells.
Vero cells were grown in Eagle's minimum
essential medium (MEM) supplemented with 5% fetal bovine serum,
penicillin (100 U/ml), and streptomycin (50 µg/ml). BHK-21 cells were
grown in MEM containing 10% fetal bovine serum and 10% tryptose
phosphate broth. RV M33 was propagated in Vero cells and used in this study.
Preparation of virion RNA and first-strand cDNA synthesis.
Monolayers of Vero cells grown in 14 150-mm-diameter dishes were
infected with RV M33. At day 3 postinfection, the culture medium was
harvested and virions were precipitated by using polyethylene glycol
(PEG) as described previously (27) and were resuspended in 1 ml of TNE buffer (10 mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA).
Virion RNA was extracted with TRIzol reagent (Gibco/BRL) following the
instructions of the manufacturer and was used for first-strand cDNA
synthesis. First-strand cDNA synthesis was carried out at 42°C for
2 h in a 20-µl reaction mixture containing viral RNA, 200 pmol
of the primer (5'-GAATTCAAGCT17-3'), 200 U of
Superscript RT RNase H
reverse transcriptase (RT)
(Gibco/BRL), and 40 U of RNase inhibitor (Promega) in a buffer provided
by the manufacturer (Gibco/BRL). The synthesized first-strand cDNA was
used as the template for the subsequent PCR amplification. A primer,
5'-CTCTCCCGAATGGCAA-3', complementary to the viral genomic
sequence 5'-TTGCCATTCGGGAGAG-3' (nt 6378 to 6491), was used
in the reaction for the synthesis of first-strand cDNA covering the
nonstructural protein gene region.
Construction of full-length RV M33 cDNA clone.
The viral
cDNA was amplified in six distinct overlapping fragments by PCR with
six pairs of primers in individual reactions. These six DNA fragments
were cut with restriction endonucleases as shown in Fig.
1 and ligated into a full-length cDNA
representing the entire viral genomic RNA. PCR amplifications were
performed in separate reactions containing cDNA, 1 pmol of primers, 0.4 mM deoxynucleoside triphosphates, 10% dimethyl sulfoxide, and proofreading TaKaRa Taq polymerase (Takara Shuzo Co., Ltd.)
in a buffer provided by the manufacturer. The PCR program consisted of
1 min at 98°C followed by 25 cycles of 20 s at 98°C, 1 s
at 56°C, and varied extension times (depending on the length of each sequence) at 70°C. Amplification of the DNA fragment covering the 5'
terminus of the viral genome was carried out with a sense primer,
5'-TTCGAATTCATTTAGGTGACACTATAG
3',
which includes the EcoRI site (italic), the SP6 RNA
polymerase promoter sequence (single underline), and the first 14 nucleotides (double underline) of the 5' terminus of the viral genome,
and with the antisense primer 5'-GGTGGGCGGGGTGGCGGTAGA-3'
(nt 1737 to 1757). For amplification of the DNA covering the 3'
terminus of the viral genome, the PCR was done with a sense primer,
5'-TACCGTCGAAATGCCCGAGT-3' (nt 9158 to 9175), and an
antisense primer, 5'-GAATTCAAGCTT15, which
includes a HindIII site immediately downstream from the poly(dT15) tract. The rest of the cDNA fragments were
amplified with the following pairs of primers: a
KpnI-NheI fragment with 5'-AGGCTCTCCGCGCGCGCGCCG-3' (sense primer; nt 1658 to 1679)
and 5'-GCACGCGACGCGCGCCCACCG-3' (antisense primer; nt 2819 to 2839); an NheI-EcoRV fragment with
5'-GCTGCTCGAGCGCGCCTACCG-3' (sense primer; nt 2770 to 2790)
and 5'-GTAGGTGGCGGCGTTCTTGAT-3' (antisense primer; nt 4220 to 4240); an EcoRV-BglII fragment with
5'-GATCCAGGCCAAACTCCGCGC-3' (sense primer; nt 4186 to 4206)
and 5'-ACGCTCAGGCTCTGGGCGGTG-3' (antisense primer; nt 5371 to 5391); and a BglII-BamHI fragment with
5'-CGCGGGAGCTCACCGACCGCT-3' (sense primer; nt 5313 to 5333) and 5'-GTCCTCGCCATTGACGGTAAGATGGCAGTT-3' (antisense primer;
nt 9351 to 9381). The assembled full-length cDNA clone was cut with EcoRI and HindIII and inserted into a
modified plasmid, pBR322, that had been digested with the same enzymes
(in this vector, the NheI-NruI fragment had been
removed to delete the Tet gene). The resulting construct was named
pBRM33.

View larger version (6K):
[in this window]
[in a new window]
|
FIG. 1.
Construction of RV M33 virus full-length cDNA clone. The
numbers on the viral genome scale refer to the distance from the 5' end
in kilobases. Six DNA fragments were amplified by proofreading TaKaRa
Taq DNA polymerase with the requisite primers as described
in Materials and Methods. The amplified DNA fragments were ligated into
a full-length cDNA representing the whole viral genome by using the
restriction sites indicated above the genome. The full-length cDNA was
cut with EcoRI and HindIII and inserted into
a modified pBR322 plasmid that had been cut with the same enzymes to
obtain the full-length cDNA clone pBRM33.
|
|
Construction of mutants.
A series of mutations was
introduced into the E1 coding region by PCR-mediated mutagenesis with
appropriate primers containing the desired nucleotide changes. To
facilitate mutagenesis, a silent mutation was introduced into pBRM33 to
create a new SphI site by changing T to A at nt 9647. For
this purpose, a fusion PCR (27) was employed with pBRM33 DNA
as a template, Pfu DNA polymerase (Stratagene), and two
pairs of primers: 5'-TACCGTCGAAATGCCCGAGT-3' (sense primer)
and 5'-AATGAGCGTACGACACGG-3' (antisense primer) and
5'-AATCTCGCATGCTGTGCC-3' (sense primer) and
5'-GAATTCAAGCTTT15-3' (antisense primer). The
PCR product was cut with BamHI and HindIII and inserted into pBRM33 (minus the
BamHI/HindIII fragment). This construct was
named pBRM34.
To construct mutants L464A, C467A, C470A, and L471A, PCR amplifications
were performed in a series of reactions with pBRM34
DNA as a template
and primers containing the desired mutations.
The mutagenic primers
were 5'-GGCACAGCATGCG
GCTAAGCC-3' for mutant
L464A, 5'-TTACTCGCATGC
GCTGCCAAATGC-3' for mutant
C467A, 5'-TTACTCGCATGCTGTGCCAAA
GCCTTGTAC-3'
for
mutant C470A, and
5'-TTACTCGCATGCTGTGCCAAATGC
GCGTACTAC-3'
for
mutant L471A (mutated nucleotides are underlined). To construct
mutants C466A and C466A/C467A, the fusion PCR described above
was
employed. The mutation was introduced into mutant C466A with
a pair of
primers, 5'-TTACTCGCA
GCCTGTGCC-3' (sense primer)
and
5'-GGCACAG
GCTGCGAGTAA-3' (antisense primer).
For mutant C466A/C467A,
a pair of primers,
5'-GGCTTACTCGCG
GCCGCCGCCAAATGC-3' (sense primer)
and 5'-GCATTTGGC
GGCGGCCGCGAGTAAGCC-3' (antisense
primer), was
used. All of the amplified DNA fragments containing the
desired
mutations were reintroduced into pBRM34, and the mutations were
verified by sequencing and restriction
analysis.
RNA transcription and transfection.
RNA transcripts were
synthesized with SP6 RNA polymerase in the presence of
m7Gpp(5')G cap analog as described previously
(29). Vero cells were transfected by a Lipofectin-mediated
transfection method. Briefly, 10 µl of RNA transcription reaction
mixture was mixed with 10 µl of Lipofectin (Gibco/BRL) at room
temperature. The mixtures were added to Vero cells that had been washed
twice with MEM. After incubation at 37°C for 2 h, the mixtures
were removed and replaced with culture medium (liquid or agarose
medium). At day 5 posttransfection, the liquid medium was harvested as
viral stock. The cells, overlaid with agarose, were stained with
neutral red to visualize viral plaques. BHK cells were transfected by electroporation as described previously (27). Briefly, BHK
cells were harvested by trypsin treatment and washed twice with
ice-cold phosphate-buffered saline without Ca2+ and
Mg2+ and resuspended at a concentration of
107/ml. RNA transcripts (20 µl) were mixed with 0.5 ml of
cells, and the mixture was transferred to a 2-mm-diameter cuvette.
Electroporation was done at room temperature with two consecutive
1.5-kV, 25-µF pulses with a Gene-pulser (Bio-Rad). After
electroporation, the cells were diluted in 10 ml of culture medium and
distributed into six-well culture plates.
RNA slot blot hybridization.
Viral RNA replication was
examined by RNA slot blot hybridization. For this purpose, total RNAs
were extracted with TRIzol reagent from Vero cells transfected with
mutant RNAs at 12, 24, or 36 h after transfection. Total RNAs (3 µg) were denatured with formamide and formaldehyde, slot blotted into
a nitrocellulose membrane, and then hybridized with minus- or
plus-strand RNA probes synthesized in vitro. For synthesis of minus- or
plus-strand RNA probes, a DNA fragment representing the 5' terminus of
the viral RNA genome (nt 1 to 1070) was cloned into plasmid pSPT19
(Pharmacia Biotech) at the SmaI site in both orientations.
The resulting constructs were used as templates for RNA transcription.
The minus- or plus-strand RNA probe was transcribed in the presence of
50 µCi of [
-32P]CTP (NEN) (3,000 Ci/mmol) with SP6
RNA polymerase. The hybridization was in a buffer (50% formamide, 6×
SSC [1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate], 1% sodium
dodecyl sulfate [SDS], 0.1% Tween-20, 100 µg of tRNA/ml)
containing minus- or plus-strand RNA probe at 55°C overnight. After
hybridization, the membrane was washed with 1× SSC containing 0.1%
SDS twice at room temperature and with 0.1× SSC containing 0.1% SDS
twice at 65°C and then exposed to X-ray film.
Metabolic labeling, immunoprecipitation, and endoglycosidase H
(endo H) digestion.
For analysis of viral structural protein
synthesis and transport, Vero cells infected with mutant viruses or BHK
cells transfected with mutant RNAs were incubated at 37°C for 40 h, washed with MEM, and starved in methionine-free medium for 30 min at
37°C. This medium was replaced with one containing
[35S]methionine (NEN) (200 µCi/ml), and the cells were
pulse-labeled for 80 min. After being labeled, the cells were chased
for various times in chase medium containing unlabeled methionine at 10 times the usual concentration. At each chase point, the chase medium was harvested for assay of released virus particles. The cells were
washed with ice-cold phosphate-buffered saline and lysed in 200 µl of
lysis buffer (1% Triton X-100, 10 mM Tris-HCl [pH 7.4], 150 mM NaCl,
1 mM EDTA, 100 µg of phenylmethylsulfonyl fluoride/ml). The lysates
were centrifuged to remove nuclei and immunoprecipitated with human
anti-rubella virus serum. For immunoprecipitation, 50 µl of lysate
was diluted to 150 µl with lysis buffer and 2 µl of human
anti-rubella virus serum was added. After incubation at 4°C for
1 h, 40 µl of 50% protein A-Sepharose beads (Pharmacia Biotech)
was added and incubated for a further 1 h at room temperature with
shaking. The beads were washed three times with lysis buffer and
resuspended in sample buffer (0.1 M citrate [pH 5.5], 0.15% SDS) and
boiled for 5 min. After centrifugation, the immunoprecipitates were
collected and mixed with SDS gel-loading buffer (62.5 mM Tris-HCl [pH
6.0], 2% SDS, 5% 2-mercaptoethanol, 500 mM sucrose) and then
analyzed by SDS-10% polyacrylamide gel electrophoresis (PAGE) under
reducing conditions.
For assay of released virus particles from transfected cells, the virus
particles in the chase medium were precipitated with
PEG and suspended
in TNE buffer as described above. Triton X-100
was added to the
suspension to a final concentration of 1%, and
immunoprecipitation and
SDS-PAGE analysis were done as described
above.
For endo H digestion, the immunoprecipitates were digested with endo H
(1 mU per 10 µl of immunoprecipitates) in the presence
of
phenylmethylsulfonyl fluoride for 14 h at 37°C. After digestion,
the immunoprecipitates were mixed with SDS gel-loading buffer
and
analyzed by SDS-PAGE.
Sucrose gradient centrifugation.
Cell lysates were layered
onto 5 to 20% (wt/wt) sucrose gradients in TNE buffer containing 0.1%
Triton X-100 and centrifuged in an SW41 rotor at 38,000 rpm for 28 h at 5°C (2). Fractionated gradients (total, 26 fractions;
25 µl per fraction) were subjected to SDS-10% PAGE under
nonreducing conditions. After electrophoresis, the proteins were
transferred to nitrocellulose membranes and probed with human
anti-rubella virus serum as described previously (24).
 |
RESULTS |
Characterization of pBRM33 cDNA clone.
RV M33 is one of the
wild-type isolates of RV. For the construction of a full-length RV M33
cDNA clone, six overlapping DNA fragments covering the entire viral
genome were individually amplified by RT-PCR with TaKaRa Taq
polymerase, which has been used successfully for construction of the
infectious cDNA clone of wild-type RV (f-Therien strain)
(21). We have used Pfu DNA polymerase in PCR
amplification of RV sequence and found that this enzyme produced smaller amounts of DNA than TaKaRa Taq polymerase and also
amplified DNA fragments over 3 kb poorly. The six DNA fragments were
assembled into a full-length cDNA by ligation after appropriate
restriction sites were used (Fig. 1). For synthesis of RNA transcripts
in vitro, an SP6 RNA polymerase promoter sequence was positioned immediately upstream of the full-length cDNA by using a primer containing the promoter sequence plus the first 14 nt at the 5' terminus of RV (M33 strain) (29). The 3'-terminal sequence
of the full-length cDNA consisted of a poly(A) tract (A31)
followed by a HindIII site, which was introduced in cDNA
synthesis by using a primer containing poly(dT15) and a
HindIII site. The assembled full-length cDNA was cut
with EcoRI and HindIII and inserted into modified plasmid, pBR322, to produce recombinant plasmid pBRM33 (Fig.
1). The HindIII site was used to linearize the plasmid
for in vitro transcription of RNA by SP6 RNA polymerase.
A second recombinant plasmid, pBRM34, was constructed, in which a new
SphI site in the E1 transmembrane domain was created
by
introduction of a silent mutation (changing T to A at nt 9647)
in the
pBRM33 clone. This clone was used for mutant construction
as described
below.
In the initial characterization of the full-length cDNA clone pBRM33,
Vero cells were transfected with RNA transcripts synthesized
from
pBRM33. At day 5 posttransfection, the culture medium containing
BRM33
virus was harvested as a viral stock. The relative growth
rate of this
BRM33 virus compared to that of the parental M33
virus was examined in
Vero cells by viral infection at a multiplicity
of infection (MOI) of
10 PFU/cell. The infected culture medium
was harvested at 12-h
intervals and replaced with fresh medium.
The virus titers at each time
point were determined and are shown
in Fig.
2A. As can be seen, the growth rates for
BRM33 and parental
M33 virus were similar, with an exponential phase
between 10 and
24 h postinfection and reaching a maximum rate at
36 h. Virus
production continued at this rate up to 60 h
after infection.
At the maximum rate, BRM33 produced 10
7
PFU/ml/12 h, which was approximately the same as the parental
M33
virus, although in the exponential phase the virus titer of
BRM33 was
twofold lower than that of M33.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
Properties of BRM33, BRM34, and M33 viruses. BRM34 virus
is a restriction site variant of BRM33 in which a new SphI
site in the E1 transmembrane domain was created by introduction of a
silent mutation (changing T to A at nt 9647) in the pBRM33 clone. (A)
Vero cells were infected with virus at an MOI of 10 PFU/cell. At 12-h
intervals, the medium was completely removed for titration and new
medium was added. The titer was determined by plaque formation on Vero
cells, and the mean titer from two experiments is shown for each time
point. , BRM33 virus; , BRM34 virus; , parental M33 virus. (B)
Vero cells were transfected with RNA and Lipofectin and overlaid with
liquid growth medium. At 24-h intervals, the medium was completely
removed for titration and new medium was added. The titer was
determined by plaque formation, and the mean titer from two experiments
is shown. , pBRM33; , pBRM34; , parental M33 RNA; The data
points for the growth curves represent two independent experiments. (C)
Morphology of plaques produced by BRM33 and BRM34. Vero cells were
transfected with RNAs from pBRM33, pBRM34, or parental M33 by using
Lipofectin, and the transfected cells were overlaid with agarose
medium. After incubation for 6 days at 35°C, the cells were stained
with neutral red.
|
|
The growth rate of BRM33 virus was also directly determined in primary
transfected cells by titration of the culture medium.
Vero cells were
transfected with pBRM33 RNA and Lipofectin. The
culture medium was
harvested daily and replaced with fresh medium.
The virus titers in the
culture medium were quantitated and are
shown in Fig.
2B. RNA
transcripts from pBRM33 produced a large
amount of infectious virus
with titer and growth kinetics similar
to those of the parental M33
RNA. The amount of virus produced
at day 1 posttransfection was
approximately 10
3 PFU/ml. After day 1, the rate of virus
production rose rapidly
until 4 days posttransfection and reached a
peak at day 5, with
the titer approaching 10
8 PFU/ml. After
that, the virus production declined due to cell
death. Taken together,
these data indicate that RNA transcribed
in vitro from pBRM33 is
capable of producing infectious virus
with a growth capacity similar to
that of the parental M33
virus.
To determine the specific infectivity of BRM33 RNA, transfected cells
were overlaid with agarose medium and viral plaques
were allowed to
develop. Vero cells transfected with BRM33 RNA
synthesized in the
presence of m
7G(5')ppp(5')G cap analog gave rise to 3 × 10
3 plaques per µg of RNA (Table
1), indicating that BRM33 RNA is
as
infectious as the RNA transcripts from another infectious cDNA
clone
derived from RV, f-Therien strain (
21). Plaques formed
from
BRM33 RNA were large (3-mm diameter), similar to those of
M33 RNA (Fig.
2C). Some smaller plaques were also present in both
M33 and BRM33
RNA-transfected cells. No plaques were detected
with BRM33 RNA
transcribed in the absence of cap analog, suggesting
that the cap
structure at the 5' terminus of the RV genome is
required for viral
infectivity.
It is notable that BRM33 virus grew more slowly than did the parental
M33 virus. The RNA transcripts synthesized with SP6
RNA polymerase
start with an additional G residue at their 5'
ends that is contributed
by the last nucleotide of the SP6 promoter.
It has been reported by
Pugachev et al. (
21) that in the cDNA
clone derived from
f-Therien strain, after one passage, 60% of
5'-terminal clones still
had the extra G, but after five passages,
no clones containing extra G
were found. After five passages,
plaques of the virus appear to be
larger and the virus grows to
a higher titer than does virus harvested
after one passage. Data
presented in Fig.
2B and C were obtained from
RNA transcript transfection
without subsequent virus passage. The lag
in virus growth and
smaller-plaque phenotype observed in BRM33 and
BRM34 viruses are
likely due to the extra G present at the 5' ends of
the RNA
transcripts.
Construction of mutants in transmembrane and cytoplasmic domains of
E1.
Possession of the infectious cDNA clone pBRM33 enabled us to
introduce mutations of interest into RV. It has been suggested that RV
E1 plays an important role in virus assembly, possibly by mediating the
interaction with nucleocapsids (11). To investigate this,
alanine substitution mutagenesis was performed in the E1 transmembrane
and cytoplasmic domains with the pBRM33 cDNA clone. Three cysteine and
two leucine residues in the E1 transmembrane and cytoplasmic domains
(Fig. 3A) were chosen as the targets in mutagenesis. In alphaviruses, it has been reported that the cysteine residues in the cytoplasmic domain of E2 are critical in the
interaction between the nucleocapsid core and the membrane-embedded E2
and E1 (8, 13, 30). To facilitate the mutagenesis process, we used the pBRM34 clone containing a created SphI site in
the E1 transmembrane domain. Since the changed base is the third base of a cysteine codon, the change is silent. The characterization of the
resulting construct, pBRM34, is shown in Fig. 2 and Table 1. These data
clearly show that there is no distinguishable difference between pBRM33
and pBRM34 in terms of virus growth, plaque size, and specific
infectivity. Thus, alteration of nucleotide T to A at position 9647 had
no effect on viral replication.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Mutations in E1 transmembrane and cytoplasmic domains
and growth curves of mutant viruses. (A) Amino acid sequence of E1
transmembrane and cytoplasmic domains and substitutions produced by
mutagenesis. The numbering is based on the sequence published by Clarke
et al. (4). (B) Growth of mutant viruses. Vero cells were
transfected with RNAs and Lipofectin and overlaid with liquid growth
medium. At 24-h intervals, the medium was removed for virus titration
and new medium was added. , BRM34; , C466A/C467A; , C467A;
, C470A; , L471A; , L464A; , C466A.
|
|
By taking advantage of the
SphI site created, we constructed
six mutants based on pBRM34 by site-directed mutagenesis: three
mutations in the E1 transmembrane domain and two mutations in
the
cytoplasmic domain. As shown in Fig.
3A, these comprised three
single-amino-acid changes of Leu 464, Cys 466, and Cys 467 to
Ala; a
double change of Cys 466 and 467 to Ala in the E1 transmembrane
domain;
and two single-amino-acid substitutions of Ala for Cys
470 and Leu 471 in the E1 cytoplasmic
domain.
Growth characteristics of mutant viruses.
To examine the
effect of these mutations on viral growth, Vero cells were transfected
with mutant RNAs by using Lipofectin and the titers of virus released
into the medium were determined. The results are shown in Fig. 3B. In
mutants C467A and C466A/C467A (transmembrane domain mutants), virus
production was severely impaired and the virus yield was only about 1%
of that of the parental BRM34 virus. Though mutant C466A also released
slightly less virus than did BRM34, its virus titer was much higher
than that of mutant C467A with the same mutation at the next position. Mutant L464A also produced slightly less virus, notably in the later
stage of infection. In the case of cytoplasmic domain mutants, mutant C470A produced amounts of virus equal to that produced by BRM34.
However, substitution of Ala for Leu 471 (next to Cys 470) had a
profound effect on virus release: mutant L471A produced about 10% as
much virus as the parental BRM34 virus. The plaques formed by C467A,
C466A/C467A, and L471A mutants in Vero cells were found to be smaller
than those of the BRM34 virus (data not shown).
RNA replication.
It is possible that the reduction in virus
yield in mutants C467A, C466A/C467A, and L471A was due to the effect of
these mutations on viral RNA replication, since the mutated nucleotides
(between nt 9642 and 9665) are located near a potential stem-and-loop
structure (nt 9669 to 9720). This stem-and-loop structure has been
shown to associate with host cell proteins (20), although
its function is unknown. To determine whether RNA replication of these
mutants was affected, both minus- and plus-strand RNA synthesis at 12, 24, or 36 h postinfection were examined in transfected Vero cells by slot blot hybridization. The amount of RNA in each dot was quantitated by densitometry of autoradiographs. RNA extracted from a
mock infection was used as a control. As shown in Fig. 4, synthesis of both minus- and
plus-strand RNA was detected as early as 12 h after transfection.
The amount of RNA was increased in both blots hybridized with either
minus- or plus-strand RNA probes from 12 to 24 h posttransfection.
No significant difference was observed between the mutants and parental
BRM34 at 24 and 36 h in either minus- or plus-strand RNA blots
except that for mutant C467A the RNA level was slightly lower than that
of the parental BRM34 at 24 h posttransfection. However, the RNA
synthesis of mutant C467A caught up with those of the other mutants at
36 h after transfection. These data indicate that the nucleotide changes introduced in the mutants had no significant effect on viral
RNA replication, though the changes in mutant C467A may slightly impair
early RNA synthesis.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 4.
RNA slot blot hybridization. Total RNA was extracted
from Vero cells transfected by Lipofectin with RNAs from mutants or
parental BRM34 at 12, 24, or 36 h posttransfection. RNA extracted
from mock-infected Vero cells was used as a control. Total RNA (3 µg)
from each culture was dotted onto nitrocellulose membranes and
hybridized with 32P-labeled RNA probes as described in
Materials and Methods. The amount of radiolabel in each dot was
quantitated by densitometry of the autoradiographs. (A) Membrane
hybridized with 32P-labeled minus-strand RNA probe. (B)
Membrane hybridized with 32P-labeled plus-strand RNA probe.
All dots were exposed to X-ray film for the same period. The data shown
represent two separate experiments.
|
|
Viral structural protein synthesis, transport, and release as virus
particles.
Since RNA replication in the mutants was not
significantly affected by the introduced mutations, viral structural
protein synthesis, transport, and release as virus particles were
examined to determine which stages of viral replication were affected. Vero cells were infected with mutant viruses, and at 40 h after infection, the cells were pulse-labeled with
[35S]methionine for 80 min and chased with unlabeled
methionine for 10 min or 5 h. The cellular lysates and
corresponding chase media containing virus particles were
immunoprecipitated with human anti-rubella virus serum and analyzed by
SDS-10% PAGE (Fig. 5). After 80 min of
pulse-labeling and a short chase of 10 min, the structural proteins E1,
E2, and capsid were observed in cells infected with all mutant and
BRM34 viruses (Fig. 5A). Two E2 forms, an ER form (39 kDa), and a Golgi
form (42 to 47 kDa) were observed (10). Below the 39-kDa E2
is a 33-kDa capsid protein. After 5 h of chase, the ER form of E2
in all mutant viruses was completely converted to the Golgi form of E2
(Fig. 5A) and virus particles were observed in the corresponding 5-h
chase medium (Fig. 5B). These results indicate that the structural
proteins in all of the mutant viruses were synthesized, cleaved, and
transported out of the ER. To compare the viral structural protein
synthesis and virus release of the mutants and parental BRM34 virus,
the amounts of intracellular E1 after 10 min of chase and extracellular E1 after 5 h of chase in each mutant virus were quantified by densitometry. The results are shown in Table
2. The amounts of intracellular E1
synthesized by mutants C470A, L464A, and C466A were equal to that of
the parental BRM34 virus, indicating that structural protein synthesis
in these mutants was similar to that of the parental BRM34 virus.
Slightly smaller amounts of structural proteins were observed in
mutants C466A/C467A, C467A, and L471A, as they produced about 60, 70, and 80%, respectively, as much E1 protein as the parental BRM34 virus
(Table 2). However, the amounts of virus released from the infected
cells by these mutants were very different. Compared to the parental
BRM34 virus, all mutants except C470A released smaller amounts of
virus. The most significant reductions in virus release were observed
in mutants C466A/C467A, C467A, and L471A, which only released about 30, 40, and 70%, respectively, of the amount of parental BRM34 virus
(Table 2). After normalizing the values to those of intracellular E1, the amounts of virus released by mutants C466A/C467A, C467A, and L471A
were 50, 57, and 88%, respectively, of that released by the parental
BRM34 virus. The normalized values are not sufficiently low to account
for the 10- to 100-fold reduction in infectivity shown in mutants
C466A/467A, C467A, and L471A, suggesting that the mutant viruses which
were released might have reduced infectivity.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 5.
Synthesis, transport, and release of structural proteins
following transfection of mutant RNAs. Vero cells were infected with
mutant or parental BRM34 viruses at an MOI of 2. At 40 h
postinfection, the infected cells were pulse-labeled for 80 min with
[35S]methionine and chased with medium containing
unlabeled methionine for 10 min or 5 h. The chase medium was
harvested, and the labeled cells were lysed with buffer containing 1%
Triton X-100. (A) The lysates were immunoprecipitated with human
anti-rubella virus serum, and the immunoprecipitates were collected
with protein A-Sepharose CL-4B and analyzed by SDS-10% PAGE. (B)
Virus particles in the chase medium were precipitated with PEG and
resuspended in TNE buffer containing 1% Triton X-100. The suspension
was immunoprecipitated with human anti-rubella virus serum and analyzed
by SDS-10% PAGE and subsequent autoradiography. The positions of
migration of RV structural proteins E1, E2, and C are shown.
|
|
Since a reduction in virus release was observed on substitution of
cysteine 467 and leucine 471, further pulse-chase experiments
were
performed to determine whether an intracellular accumulation
of
structural proteins occurred in the two mutants that would
indicate a
possible block in virus budding. BHK cells were transfected
with mutant
C467A or L471A or parental BRM34 RNA and incubated
for 40 h. The
transfected cells were pulse-labeled with [
35S]methionine
for 80 min and then incubated with excess unlabeled
methionine for 10 min and 3, 6, and 9 h. At each chase point,
the cell lysates and
corresponding chase medium were immunoprecipitated
and analyzed by
SDS-10% PAGE (Fig.
6A to C). The amount
of radiolabel
in intracellular E1 at each point was quantitated by
densitometry.
The ratios of radiolabel in E1 at 3, 6, and 9 h of
chase to that
at 10 min of chase for mutants C467A, L471A, and parental
BRM34
were plotted and are shown in Fig.
6D. In parental BRM34 after
3 h of chase, the intracellular E1 was 33% of that at 10 min of
chase, whereas about 85 and 65% of E1 radiolabel in C467A and
L471A,
respectively, were intracellular. After a 6-h chase, most
of the
intracellular E1 in BRM34 and mutant L471A was released
from the cells,
with only 11 and 23%, respectively, of E1 remaining
intracellular.
However, in mutant C467A, most of the E1 (70%)
remained intracellular.
By comparison with the ratios of E1 at
each chase point between the
mutants and parental BRM34, it is
clear that the E1 protein accumulated
in mutants C467A and L471A
during the chase period, with mutant C467A
accumulating more proteins
than mutant L471A. Thus, these results,
consistent with the results
shown in Fig.
3B and
5 and Table
2, suggest
that the defect in
virus release is at the late stage of virus
assembly. It is worth
noting that the reduction in radiolabel in
intracellular E1 may
not be due solely to release of E1 from the cells.
Quantitation
of the release of E1 in the mutants revealed that the
reduction
in intracellular E1 was not proportional to the increase in
the
release of E1 from the cells (data not shown), indicating that
degradation of intracellular E1 might occur expecially after 9
h
of chase. Nonetheless, less virus was released in mutants C467A
and
L471A at each chase point compared to the parental virus.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 6.
Pulse-chase analysis of intracellular structural
proteins. BHK cells were transfected with mutant C467A, L471A, or
parental BRM34 RNAs and incubated for 40 h. The transfected cells
were pulse-labeled with [35S]methionine for 80 min and
then chased with unlabeled methionine for 10 min or 3, 6, or 9 h.
The cell lysates and corresponding chase media were immunoprecipitated
with human anti-rubella virus serum and analyzed by SDS-10% PAGE. (A)
Parental BRM34; (B) mutant L471A; (C) mutant C467A. (D) The amount of
radiolabel in intracellular E1 at each time point was quantitated by
densitometry of the autoradiographs. The ratios of radiolabel in E1 at
3, 6, and 9 h of chase to that at 10 min of chase (set to 1) are
shown. , parental BRM34; , L471A; , C467A.
|
|
To examine whether the transport of RV structural proteins was
affected, the immunoprecipitates of cell lysates were treated
with endo
H. RV structural proteins undergo extensive glycosylation
during
transport from the ER and passage through the Golgi complex
to the cell
surface (
10). The acquisition of resistance to endo
H
digestion by RV structural proteins is an indication that they
have
reached the
cis-Golgi compartment (
10,
23). As
shown
in Fig.
7, during the 10-min chase
period, the ER form of E2 in
all mutants was sensitive to endo H
digestion, resulting in a
reduction in apparent molecular mass from 39 to 31 kDa. However,
treatment of E1 with endo H led to only partial
digestion (Fig.
7). Complete digestion would reduce the molecular mass
of E1 from
58 to 51 kDa. After 6 h of chase, the ER form of E2 in
all mutants
became completely endo H resistant. The majority of E1 also
became
resistant. E1 contains three glycosylation sites, and it appears
that only one site is processed to add a complex type of glycan
(
10). No change in molecular mass was found with capsid
after
endo H digestion. These results indicate that E1 and E2 of all
mutants were transported normally.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 7.
endo H treatment of structural proteins.
Immunoprecipitates were isolated as described in the legend to Fig. 5,
digested with endo H at 37°C for 14 h, and then analyzed by
SDS-10% PAGE and autoradiography. , not treated with endo H; +,
treated with endo H. The positions of molecular mass markers are shown
on the right (in kilodaltons).
|
|
E2/E1 heterodimer formation.
RV E2 and E1 form a noncovalent
protein complex, not dissociated by nonionic detergents, and the
formation of intracellular E2/E1 heterodimers can be detected by
sedimentation analysis in sucrose gradients (1). To examine
whether E2/E1 heterodimer formation was affected in mutants C467A and
L471A, we performed sucrose gradient sedimentation analysis of cellular
lysates treated with Triton X-100. Vero cells were infected with the
mutant or the parental BRM34 viruses. At 3 days postinfection, Triton
X-100 lysates were prepared and centrifuged on a 5 to 20% sucrose
gradient followed by fractionation. The fractionated gradients were
analyzed by SDS-PAGE under nonreducing conditions. RV antigens
transferred to membranes were detected with human anti-rubella virus
serum. E1 protein was found in all fractions of the gradient, whereas E2 was found in two regions (Fig. 8).
According to Baron and Forsell (1), the slower-migrating E1
(fractions 16 to 20) was monomeric E1 and the faster-sedimenting peak
(fractions 5 to 15) contained E2/E1 heterodimers as well as E1
oligomers (Fig. 8). Therefore, it is likely that the fractions between
11 and 15 contained mostly E2/E1 heterodimer. Comparison of the
sedimentation profiles of BRM34, L471A, and C467A shows that E2 and E1
form a heterodimer in the mutants, unaffected by the introduced
mutations. RV E2 protein is heavily but heterogeneously glycosylated.
The heavier E2 fractions (5 to 10) contained mostly Golgi-form E2,
while the lighter fractions (11 to 20) contained mostly ER-form E2 and
some unglycosylated E2 with a molecular mass of 31 kDa (Fig. 8).

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 8.
E2/E1 heterodimer formation. Vero cells were infected
with C467A, L471A, or parental BRM34 virus. After 3 days of infection,
the cells were lysed with buffer containing 1% Triton X-100. The
lysates were applied to a 5 to 20% (wt/wt) sucrose gradient in TNE
buffer containing 0.1% Triton X-100. After centrifugation in an SW41
rotor at 5°C and at 38,000 rpm for 28 h, the gradients were
fractionated from the bottom of the tube. Samples (25 µl per
fraction) were analyzed by SDS-10% PAGE under nonreducing conditions
followed by immunoblotting and probing with human anti-rubella virus
serum. Note that fractions 5 to 20 are shown in the figure.
Sedimentation is from right to left. The capsid protein was found in
the pellet fractions at the bottom of the gradient. The positions of
molecular mass markers are shown on the right (in kilodaltons).
|
|
 |
DISCUSSION |
In this study, we constructed a full-length cDNA clone, pBRM33,
derived from the M33 strain of RV. The RNA transcripts synthesized from
pBRM33 in vitro were highly infectious, with specific infectivity approaching 104 plaques per µg of RNA, and produced
viruses showing characteristics of growth rate and plaque size similar
to those of the parental M33 virus. The amounts of virus produced by
BRM33 were comparable to those produced by parental M33
(107 PFU/ml). The full-length cDNA in pBRM33 plasmid is
also stable, without any loss of infectivity after several passages in
Escherichia coli. During construction of the cDNA clone, we
found that purification of the virion RNA used in RT-PCR by
oligo(dT)-cellulose chromatography, as was reported previously, was not
necessary (21). Interestingly, we were also able to amplify
a DNA fragment that covered the region between KpnI (nt
1723) and NheI (nt 2800) previously reported not to be
amplified (21). The reasons are not clear. Perhaps there are
differences in RNA secondary structure between M33 and f-Therien
viruses or the primers used in our experiments are more efficient.
We also demonstrated the feasibility of using an infectious cDNA clone
for the analysis of RV RNA replication and gene expression. We were
able to detect the synthesis of minus- or plus-strand RNA in Vero cells
transfected with RNA transcripts by slot blot hybridization as early as
12 h posttransfection and to express larger amounts of structural
proteins in BHK cells by electroporation of RNA transcripts without
using amplified virus. This expression system is important in studying
RV mutants with higher frequencies of reversion or second-site
mutation, since it allows phenotypic analysis of the mutants after one
round of RNA replication. The system also permits the study of null
mutants from which virus cannot be rescued.
It has been proposed that E1 in the E2/E1 heterodimer may be involved
in the assembly of RV, possibly through interaction with nucleocapsids
by its cytoplasmic domain (11). We studied the role of E1 in
viral assembly by introducing mutations in its transmembrane and
cytoplasmic domains into our constructed infectious cDNA clone.
Nucleotide changes introduced in the transmembrane or cytoplasmic
domain did not significantly alter the rate of minus- or plus-strand
RNA synthesis, and all mutant RNAs replicated normally.
Biosynthesis studies showed that E2 and E1 were synthesized and
efficiently cleaved in all mutants, although slightly reduced levels of
protein synthesis were observed in mutants C466A/C467A and C467A. Both
E2 and E1 were also transported normally, as evidenced by pulse-chase
experiments in which E2 protein synthesized in the ER was completely
converted to the Golgi form with a higher molecular mass of 42 to 47 kDa, and both E2 and E1 acquired endo H resistance after the chase.
However, a reduction in virus release was observed with all mutants
except C470A. Substitution of Ala for Leu 471 in the cytoplasmic domain
and of Ala for Cys 467 in the transmembrane domain led to significant
reductions in virus release. This defect in virus release was not due
to a failure of E2-E1 interaction, since the mutated E1 formed
heterodimers with E2 (Fig. 8). However, an accumulation of
intracellular structural proteins was observed during pulse-chase
experiments (Fig. 6). Thus, these results indicate that E1 plays a
critical role at a very late stage of viral assembly and probably in
the final virus budding process. Hobman et al. (11) have
studied RV assembly by expression of RV structural proteins with an
expression vector. They showed that COS cells transiently expressing
the structural proteins secrete virus-like particles into the medium in
a capsid-dependent manner. Deleting or replacing the E1 cytoplasmic
domain was found to inhibit the secretion of RV structural proteins
from the transfected cells, suggesting that the cytoplasmic domain of
E1 is required for virus assembly. However, the effect of deletion of
the cytoplasmic domain on E2/E1 heterodimer formation and transport was
not examined. Nonetheless, the results of our studies are consistent
with those of Hobman et al., indicating that the E1 cytoplasmic domain
is involved in virus assembly. It is unclear how mutation of Leu 471 in
the E1 cytoplasmic domain affects virus assembly. However, we found
that substitution of Tyr 472 by Ala (next to Leu 471) also resulted in
severe reduction in virus release (unpublished data). In contrast, no
inhibition of virus production was observed with mutation of Cys 470 in
the cytoplasmic domain, suggesting that the leucine residue at position
471 may represent the N terminus of the interactive region in the
cytoplasmic domain. The reduction in virus release observed with the
mutant L471A, therefore, is likely caused by altered interaction
between its E1 cytoplasmic domain and other structural proteins,
possibly nucleocapsids. Similar results were reported with
alphaviruses, in which it is known that virus budding is driven by the
interaction of the E2 cytoplasmic domain with nucleocapsids
(25). Any changes in the amino acid residues that form the
N-terminal region of the E2 cytoplasmic domain were found to be
deleterious to alphavirus assembly (8, 13, 19, 28, 30).
Substitution of Cys 467 in the E1 transmembrane domain dramatically
reduced virus release, indicating that the transmembrane domain of E1
is also involved in virus assembly. It is not clear at present how the
alteration of Cys 467 influences virus assembly. E1 is known to undergo
palmitoylation (10, 26). The Cys 467 is, therefore, one of
the possible sites for attachment of palmitic acid, as suggested by
others (7). Palmitoylation usually results in better
anchoring of membrane proteins in cellular membranes. If this is the
site for palmitoylation, mutation of Cys 467 would block fatty acid
acylation in E1 and would lead to weakly anchored E1 protein. Since our
experimental results showed that substitution of Ala for Cys 467 did
not affect E2/E1 heterodimer formation, therefore, it is tempting to
speculate that the palmitoylation of Cys 467 is required for better E1
anchoring, thereby allowing correct positioning of its cytoplasmic
domain in the cytoplasm. This possibility is under investigation.
 |
ACKNOWLEDGMENTS |
This work was supported by a grant from the Medical Research
Council of Canada. Shirley Gillam is an investigator of British Columbia's Children's Hospital Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology and Laboratory Medicine, University of British Columbia,
Research Institute, 950 West 28th Ave., Vancouver, British Columbia V5Z 4H4, Canada. Phone: (604) 875-2474. Fax: (604) 875-2496. E-mail: gillam{at}wpog.childhosp.bc.ca.
 |
REFERENCES |
| 1.
|
Baron, M. D., and K. Forsell.
1991.
Oligomerization of the structural proteins of rubella virus.
Virology
185:811-819[Medline].
|
| 2.
|
Barth, B.-U.,
J. M. Wahlberg, and H. Garoff.
1995.
The oligomerization reaction of the Semiliki Forest virus membrane protein subunits.
J. Cell Biol.
128:283-291[Abstract/Free Full Text].
|
| 3.
|
Chen, J.-P.,
J. H. Strauss,
E. G. Strauss, and T. K. Frey.
1996.
Characterization of the rubella virus nonstructural protease domain and its cleavage site.
J. Virol.
70:4707-4713[Abstract].
|
| 4.
|
Clarke, D. M.,
T. W. Loo,
I. Hui,
P. Chong, and S. Gillam.
1987.
Nucleotide sequence and in vitro expression of rubella virus 24S subgenomic mRNA encoding the structural proteins E1, E2 and C.
Nucleic Acids Res.
15:3041-3057[Abstract/Free Full Text].
|
| 5.
|
Clarke, D. M.,
T. W. Loo,
H. McDonald, and S. Gillam.
1988.
Expression of rubella virus cDNA coding for the structural proteins.
Gene
65:23-30[Medline].
|
| 6.
|
Dominguez, G.,
C. Wang, and T. K. Frey.
1990.
Sequence of the genome RNA of rubella virus: evidence for genetic rearrangement during Togavirus evolution.
Virology
177:225-238[Medline].
|
| 7.
|
Frey, T. K.
1994.
Molecular biology of rubella virus.
Adv. Virus Res.
44:69-160[Medline].
|
| 8.
|
Gaedigk-Nitschko, K., and M. J. Schlesinger.
1991.
Site-directed mutations in Sindbis virus E2 glycoprotein's cytoplasmic domain and the 6K protein lead to similar defects in virus assembly and budding.
Virology
183:206-214[Medline].
|
| 9.
|
Hobman, T. C., and S. Gillam.
1989.
In vitro and in vivo expression of rubella virus glycoprotein E2: the signal peptide is contained in the C-terminal region of capsid protein.
Virology
173:241-250[Medline].
|
| 10.
|
Hobman, T. C.,
M. L. Lundstrom, and S. Gillam.
1990.
Processing and intracellular transport of rubella virus structural proteins in COS cells.
Virology
178:122-133[Medline].
|
| 11.
|
Hobman, T. C.,
M. L. Lundstrom,
C. A. Mauracher,
L. Woodward,
S. Gillam, and M. G. Farquhar.
1994.
Assembly of rubella virus structural proteins into virus-like particles in transfected cells.
Virology
202:574-585[Medline].
|
| 12.
|
Hobman, T. C.,
R. Shukin, and S. Gillam.
1988.
Translocation of rubella virus glycoprotein E1 into the endoplasmic reticulum.
J. Virol.
62:4259-4264[Abstract/Free Full Text].
|
| 13.
|
Ivanova, L., and M. J. Schlesinger.
1993.
Site-directed mutations in the Sindbis virus E2 glycoprotein identify palmitoylation sites and affect virus budding.
J. Virol.
67:2546-2551[Abstract/Free Full Text].
|
| 14.
|
Lopes, S.,
J. Yao,
R. Kuhn,
E. G. Strauss, and J. H. Strauss.
1994.
The E2 glycoprotein-nucleocapsid interaction is required for alphavirus assembly.
J. Virol.
68:1316-1323[Abstract/Free Full Text].
|
| 15.
|
Matthews, R. E. F.
1982.
Classification and nomenclature of viruses.
Intervirology
17:1-99[Medline].
|
| 16.
|
McDonald, H.,
T. C. Hobman, and S. Gillam.
1991.
The influence of capsid protein cleavage on the processing of E2 and E1 glycoproteins of rubella virus.
Virology
183:52-56[Medline].
|
| 17.
|
Oker-Blom, C.
1984.
The gene order for rubella virus structural proteins is NH2-C-E2-E1-COOH.
J. Virol.
51:964-973.
|
| 18.
|
Oker-Blom, C.,
I. Ulmanen,
L. Kääriäinen, and R. F. Pettersson.
1984.
Rubella virus 40S genome RNA specifies a 24S subgenomic mRNA that codes for a precursor to structural proteins.
J. Virol.
49:403-408[Abstract/Free Full Text].
|
| 19.
|
Owen, K. E., and R. J. Kuhn.
1997.
Alphavirus budding is dependent on the interaction between the nucleocapsid and hydrophobic amino acid on the cytoplasmic domain of the E2 envelope glycoprotein.
Virology
230:187-196[Medline].
|
| 20.
|
Pogue, G. P.,
X.-Q. Cao,
N. K. Singh, and H. L. Nakhasi.
1993.
5' sequences of rubella virus RNA stimulate translation of chimeric RNA and specifically interact with two host encoded proteins.
J. Virol.
67:7106-7117[Abstract/Free Full Text].
|
| 21.
|
Pugachev, K. V.,
E. S. Abernathy, and T. K. Frey.
1997.
Improvement of the specific infectivity of the rubella virus (RUB) infectious clone: determinants of cytopathogenicity induced by RUB map to the nonstructural proteins.
J. Virol.
71:562-568[Abstract].
|
| 22.
|
Pugachev, K. V.,
E. S. Abernathy, and T. K. Frey.
1997.
Genomic sequence of the RA27/3 vaccine strain of rubella virus.
Arch. Virol.
142:1165-1180[Medline].
|
| 23.
|
Qiu, Z.,
T. C. Hobman,
H. L. McDonald,
N. O. L. Seto, and S. Gillam.
1992.
Role of N-linked oligosaccharides in processing and intracellular transport of E2 glycoprotein of rubella virus.
J. Virol.
66:3514-3521[Abstract/Free Full Text].
|
| 24.
|
Qiu, Z.,
D. Ou,
H. Wu,
T. C. Hobman, and S. Gillam.
1994.
Expression and characterization of virus-like particles containing rubella virus structural proteins.
J. Virol.
68:4086-4091[Abstract/Free Full Text].
|
| 25.
|
Strauss, J. H., and E. G. Strauss.
1994.
The alphaviruses: gene expression, replication, and evolution.
Microbiol. Rev.
58:491-562[Abstract/Free Full Text].
|
| 26.
|
Waxham, M. N., and J. S. Wolinsky.
1985.
A model of the structural organization of rubella virions.
Rev. Infect. Dis.
7(Suppl. 1):S133-S139.
|
| 27.
|
Yao, J.,
E. G. Strauss, and J. H. Strauss.
1996.
Interaction between PE2, E1, and 6K required for assembly of alphaviruses studied with chimeric viruses.
J. Virol.
70:7910-7920[Abstract].
|
| 28.
|
Yao, J.,
E. G. Strauss, and J. H. Strauss.
1998.
Molecular genetic study of the interaction of Sindbis virus E2 with Ross River E1 for virus budding.
J. Virol.
72:1418-1423[Abstract/Free Full Text].
|
| 29.
|
Yao, J.,
D. Yang,
P. Chong,
D. Hwang,
Y. Liang, and S. Gillam.
1998.
Proteolytic processing of rubella virus non-structural proteins.
Virology
246:74-82[Medline].
|
| 30.
|
Zho, H.,
B. Lindqvist,
H. Garoff,
C. H. von Bonsdorf, and P. Liljestrom.
1994.
A tyrosine-based motif in the cytoplasmic domain of the alphavirus envelope protein is essential for budding.
EMBO J.
13:4204-4211[Medline].
|
Journal of Virology, June 1999, p. 4622-4630, Vol. 73, No. 6
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ilkow, C. S., Mancinelli, V., Beatch, M. D., Hobman, T. C.
(2008). Rubella Virus Capsid Protein Interacts with Poly(A)-Binding Protein and Inhibits Translation. J. Virol.
82: 4284-4294
[Abstract]
[Full Text]
-
Overby, A. K., Popov, V. L., Pettersson, R. F., Neve, E. P. A.
(2007). The Cytoplasmic Tails of Uukuniemi Virus (Bunyaviridae) GN and GC Glycoproteins Are Important for Intracellular Targeting and the Budding of Virus-Like Particles. J. Virol.
81: 11381-11391
[Abstract]
[Full Text]
-
Law, L. J., Ilkow, C. S., Tzeng, W.-P., Rawluk, M., Stuart, D. T., Frey, T. K., Hobman, T. C.
(2006). Analyses of Phosphorylation Events in the Rubella Virus Capsid Protein: Role in Early Replication Events. J. Virol.
80: 6917-6925
[Abstract]
[Full Text]
-
Tzeng, W.-P., Matthews, J. D., Frey, T. K.
(2006). Analysis of rubella virus capsid protein-mediated enhancement of replicon replication and mutant rescue.. J. Virol.
80: 3966-3974
[Abstract]
[Full Text]
-
Beatch, M. D., Everitt, J. C., Law, L. J., Hobman, T. C.
(2005). Interactions between Rubella Virus Capsid and Host Protein p32 Are Important for Virus Replication. J. Virol.
79: 10807-10820
[Abstract]
[Full Text]
-
Law, L. M. J., Everitt, J. C., Beatch, M. D., Holmes, C. F. B., Hobman, T. C.
(2003). Phosphorylation of Rubella Virus Capsid Regulates Its RNA Binding Activity and Virus Replication. J. Virol.
77: 1764-1771
[Abstract]
[Full Text]
-
Lee, J.-Y., Bowden, D. S.
(2000). Rubella Virus Replication and Links to Teratogenicity. Clin. Microbiol. Rev.
13: 571-587
[Abstract]
[Full Text]
-
Qiu, Z., Yao, J., Cao, H., Gillam, S.
(2000). Mutations in the E1 Hydrophobic Domain of Rubella Virus Impair Virus Infectivity but Not Virus Assembly. J. Virol.
74: 6637-6642
[Abstract]
[Full Text]
-
Liang, Y., Yao, J., Gillam, S.
(2000). Rubella Virus Nonstructural Protein Protease Domains Involved in trans- and cis-Cleavage Activities. J. Virol.
74: 5412-5423
[Abstract]
[Full Text]
-
Liang, Y., Gillam, S.
(2000). Mutational Analysis of the Rubella Virus Nonstructural Polyprotein and Its Cleavage Products in Virus Replication and RNA Synthesis. J. Virol.
74: 5133-5141
[Abstract]
[Full Text]
-
Yao, J., Gillam, S.
(2000). A Single-Amino-Acid Substitution of a Tyrosine Residue in the Rubella Virus E1 Cytoplasmic Domain Blocks Virus Release. J. Virol.
74: 3029-3036
[Abstract]
[Full Text]